Pfizer
Biotech

Pfizer cans twice-daily oral obesity program

Months after making twice-daily danuglipron its top prospect, Pfizer has dropped the program after 50%+ of patients dropped out of a midphase trial.
Nick Paul Taylor Dec 1, 2023 8:30am
cough quarantine COVID sick cold flu

After Merck's cough drama, GSK knew what to do with Bellus asset

Nov 30, 2023 8:00am
Potrero Accuryn

Kidney monitor maker Potrero Medical files for bankruptcy

Dec 1, 2023 4:40pm
money financing funds

Fierce Biotech Fundraising Tracker: Arrivo, Vivodyne & more

Dec 1, 2023 2:08pm
syringes

FDA recommends avoiding plastic syringes made in China

Dec 1, 2023 11:47am
merger acquisition deal

Concentra back with another buyout offer, this time for LianBio

Dec 1, 2023 11:03am
CRO News

Merck turns to Acclinate to boost diversity of cancer trials

Nov 30, 2023 8:58am

QuantHealth debuts AI-based program to simulate trials at scale

Nov 29, 2023 10:31pm

RetinAI Medical joins non-profit macular degeneration initiative

Nov 29, 2023 11:36am

BioVie blames trial sites for phase 3 Alzheimer’s drug fail

Nov 29, 2023 10:05am